Last reviewed · How we verify
Imiquimod 3.75% Cream
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions. Used for Actinic keratosis, Basal cell carcinoma, Genital warts.
At a glance
| Generic name | Imiquimod 3.75% Cream |
|---|---|
| Sponsor | Medical University of Graz |
| Drug class | TLR7 agonist |
| Target | TLR7 (Toll-like receptor 7) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Oncology |
| Phase | FDA-approved |
Mechanism of action
Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that enhance local immune activation. This immune stimulation promotes clearance of abnormal skin cells and has antiviral and anti-tumor properties. The 3.75% cream formulation is designed for topical application to affected skin areas.
Approved indications
- Actinic keratosis
- Basal cell carcinoma
- Genital warts
Common side effects
- Local skin irritation (erythema, erosion, flaking)
- Pruritus
- Burning sensation
- Flu-like symptoms
Key clinical trials
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch (NA)
- Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream (PHASE4)
- Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma (NA)
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream (PHASE2)
- Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis (PHASE3)
- Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy (PHASE4)
- Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis. (PHASE1)
- Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiquimod 3.75% Cream CI brief — competitive landscape report
- Imiquimod 3.75% Cream updates RSS · CI watch RSS
- Medical University of Graz portfolio CI